Stockscreener 앱 받기
30.47
0.59%
-0.18
전일 마감가:
$30.65
열려 있는:
$29.99
하루 거래량:
2.15M
Relative Volume:
0.89
시가총액:
$3.71B
수익:
$1.24B
순이익/손실:
$209.00M
주가수익비율:
18.35
EPS:
1.6605
순현금흐름:
$-94.86M
1주 성능:
+1.74%
1개월 성능:
-4.72%
6개월 성능:
+31.00%
1년 성능:
+220.06%
1일 변동 폭
$29.65
$30.57
1주일 범위
$28.66
$31.25
52주 변동 폭
$8.64
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
명칭
Indivior Pharmaceuticals Inc
전화
804-379-1090
주소
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
30.47 | 3.71B | 1.24B | 209.00M | -94.86M | 1.6605 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-07-22 | 재개 | Jefferies | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-23 | 개시 | Piper Sandler | Overweight |
| 2024-04-03 | 개시 | Craig Hallum | Buy |
| 2023-07-13 | 개시 | Northland Capital | Outperform |
모두보기
Indivior Pharmaceuticals Inc 주식(INDV)의 최신 뉴스
Indivior Pharmaceuticals Inc. R (E7P.F) Insider Ownership & Holdings - Yahoo! Finance Canada
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
JPMorgan Chase & Co. Has $5.01 Million Holdings in Indivior PLC $INDV - MarketBeat
Did Potential Jail Staffing Efficiencies From SUBLOCADE® Just Shift Indivior Pharmaceuticals' (INDV) Investment Narrative? - Sahm
Indivior Pharmaceuticals Inc. R (E7P.F) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - MSN
INDV Technical Analysis & Stock Price Forecast - Intellectia AI
Indivior Pharmaceuticals, Inc. (INDV) Stock forecasts - Yahoo Finance UK
What Indivior Pharmaceuticals (INDV)'s Prison Cost Model Findings Mean For Shareholders - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - The Globe and Mail
Indivior Pharmaceuticals, Inc - Reuters
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView
New Cost Impact Model Highlights Potential Benefits of Monthly Injectable Buprenorphine - National Today
New Cost Model Shows Monthly Injectable Buprenorphine Can Reduce Staffing Burdens in Prisons - National Today
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities - The Manila Times
Monthly opioid addiction shot may cut jail staffing, model estimates - Stock Titan
Zacks.com spotlights Indivior, Ciena, and Ultra Clean as notable mentions - Bitget
Zacks.com featured highlights include Indivior, Ciena and Ultra Clean - Yahoo Finance
New Model Puts Indivior’s SUBLOCADE Correctional Opportunity In Focus - Sahm
Indivior PLC (NASDAQ:INDV) Short Interest Up 21.7% in March - MarketBeat
Indivior: Still Attractive After FY25 Earnings Beat (NASDAQ:INDV) - Seeking Alpha
Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its 200% One Year Surge? - simplywall.st
Hennion & Walsh Asset Management Inc. Purchases 96,177 Shares of Indivior PLC $INDV - MarketBeat
If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - Stock Titan
SG Americas Securities LLC Buys 363,829 Shares of Indivior PLC $INDV - MarketBeat
Indivior PLC (NASDAQ:INDV) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Levi & Korsinsky Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - MarketScreener
Indivior (INDV) posts 2025 growth, SUBLOCADE gains and $400M buyback in 2026 proxy - Stock Titan
Suboxone Market Size Forecasts 2026-2033: Analyzing Industry - openPR.com
Indivior PLC Stock Faces Uncertainty Amid U.S. Domicile Shift and OUD Market Focus - AD HOC NEWS
Indivior Pharmaceuticals Inc (INDV) Shares Up 5.07% on Mar 25 - GuruFocus
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Down 12.9% Over the Past Month: Reasons to Consider Purchasing Indivior Pharmaceuticals Inc. (INDV) During the Decline - Bitget
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
[SCHEDULE 13G] Indivior Pharmaceuticals, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Indivior Pharmaceuticals to report Q4 earnings: What's in the cards? - MSN
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Recent Share Price Weakness - Sahm
Implied volatility surging for Indivior Pharmaceuticals stock options - MSN
Indivior Pharmaceuticals Inc (INDV) Shares Gap Down to $29.44 on Mar 20 - GuruFocus
Indivior (NASDAQ:INDV) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Goldentree Asset Management LP Makes New Investment in Indivior PLC $INDV - MarketBeat
Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program - MSN
Indivior Issues $500 Million Convertible Senior Notes Offering - TipRanks
[Form 4] Indivior Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Indivior Pharmaceuticals Raises $500 Million Via 0.625% Convertible Notes Due 2031 - TradingView
Indivior Pharmaceuticals Survey Reveals Gaps in Medications for Opioid Use Disorder in U.S. Jails and Prisons - Quiver Quantitative
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder - GlobeNewswire
Indivior Pharmaceuticals Inc (INDV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Indivior Pharmaceuticals Inc 주식 (INDV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kingsley Stuart A | Director |
Mar 06 '26 |
Buy |
31.86 |
940 |
29,953 |
5,582 |
| Ryan Barbara | Director |
Mar 09 '26 |
Buy |
32.56 |
31 |
1,009 |
5,716 |
| Ryan Barbara | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
1,963 |
| Humphreys Keith | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
5,802 |
| NINIVAGGI DANIEL A | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,923 |
| Stejbach Mark | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,847 |
| Wheadon David E. | Director |
Jan 05 '26 |
Buy |
35.39 |
1,771 |
62,680 |
14,395 |
1.11%
자본화:
|
볼륨(24시간):